Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04895709 · ClinicalTrials.gov registry record · Phase 1

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

A Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 1
Development phase
949
Enrollment target
20
Study locations

NCT04895709 is a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 949 participants, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (44% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04895709, a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 1
Development phase
949 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.

Conditions Studied

Non-Small Cell Lung Cancer Melanoma Cervical Cancer Urothelial Carcinoma Pancreatic Adenocarcinoma Ovarian Neoplasms Squamous Cell Carcinoma of Head and Neck Carcinoma, Renal Cell Microsatellite Stable Colorectal Cancer Gastric/Gastroesophageal Junction Adenocarcinoma

Interventions

  • DRUG Docetaxel
  • DRUG BMS-986340
  • DRUG BMS-936558-01

Study Locations (20)

California

  • Community Cancer Institute - Clovis
  • USC/Norris Comprehensive Cancer Center - Los Angeles
  • Hoag Memorial Hospital Presbyterian - Newport Beach

New York

  • Local Institution - 0006 - New York
  • Local Institution - 0002 - New York

Tennessee

  • Local Institution - 0063 - Nashville
  • Vanderbilt University Medical Center - Nashville

New South Wales

  • Blacktown Hospital - Blacktown
  • Liverpool Hospital - Liverpool

Victoria

  • Cabrini Hospital - Malvern - Malvern
  • St Vincent's Hospital - Melbourne

Iowa

  • Local Institution - 0062 - Iowa City

New Jersey

  • John Theurer Cancer Center - Hackensack

Oregon

  • Local Institution - 0001 - Portland

Trial Details

FieldValue
Enrollment Target 949 participants
Start Date 2021-05-27
Est. Completion 2028-07-07
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04895709

The ClinicalTrials.gov registry entry for NCT04895709 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 949 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (44% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.

NCT04895709 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, New York, Tennessee.

Frequently Asked Questions

What is clinical trial NCT04895709 about?

NCT04895709 is a clinical study titled "A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors". The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced soli...

What is the current status of trial NCT04895709?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 949 participants. The study started on 2021-05-27. Estimated completion is 2028-07-07.

What conditions does trial NCT04895709 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Cervical Cancer, Urothelial Carcinoma, Pancreatic Adenocarcinoma.

What interventions are being tested in trial NCT04895709?

The interventions under investigation include: Docetaxel (DRUG), BMS-986340 (DRUG), BMS-936558-01 (DRUG).

Who is sponsoring clinical trial NCT04895709?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04895709 being conducted?

This trial has 20 study locations across California, Iowa, New Jersey, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Melanoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.